• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Rivaroxaban has no net clinical benefit over enoxaparin for thromboprophylaxis in acutely ill patients

bys25qthea
February 6, 2013
in Cardiology, Surgery
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Feb 6th – NEJM – Extended-duration rivaroxaban was superior to standard-duration enoxaparin for thromboprophylaxis, but was associated with increased bleeding risk.

[tabs tab1=”2MM Rundown” tab2= “2MM Full Report”]

[tab]

Image: PD

1. Standard-duration rivaroxaban had no net clinical benefit over standard-duration enoxaparin for thromboprophylaxis in acutely ill hospitalized patients.

2. Extended-duration rivaroxaban was superior to standard-duration enoxaparin for thromboprophylaxis, but was associated with increased bleeding risk.

RELATED REPORTS

Direct oral anticoagulants increase bleeding risk after intracerebral hemorrhage in patients with atrial fibrillation

#VisualAbstract: Reduced-Dose was Not Non-Inferior to Full-Dose Direct Oral Anticoagulants in Venous Thromboembolism Patients

Abelacimab reduces bleeding risk compared to rivaroxaban in atrial fibrillation

Preventing thromboembolism in acutely ill hospitalized patients is a balancing act between reducing clot formation and the increasing bleeding risk. As some studies have shown the risk of thromboembolism persists after discharge from the hospital, this study compared thromboprophylaxis with standard-duration enoxaparin vs. extended-duration rivaroxaban

For preventing thromboembolism, rivaroxaban was non-inferior to enoxaparin over the standard-duration, and superior to enoxaparin over the extended-duration. However, rivaroxaban was also associated a higher risk of clinically relevant bleeding compared to enoxaparin. The study did not establish a net clinical benefit of choosing rivaroxaban over enoxaparin after accounting for both efficacy and safety.

This study affirms that an optimal treatment for thromboprophylaxis has yet to emerge. Better patient stratification based on bleeding risks is needed in order to maximize the clinical benefit of rivaroxaban.

Click to read the study in NEJM

[/tab]

[tab]

Image: PD

1. Rivaroxaban had no net clinical benefit over enoxaparin for short-term thromboprophylaxis in acutely ill hospitalized patients.

2. Extended-duration rivaroxaban was superior to standard-duration enoxaparin for thromboprophylaxis, but was associated with increased bleeding risk.

This [randomized, double-blind] trial compared rivaroxaban to enoxaparin for thromboprophylaxis in hospitalized patients.

Patients were randomly assigned one of two treatment regimens – the enoxaparin group received enoxaparin sub-Q 40 mg qd for 10±4 days (and PO placebo for 35±4 days); the rivaroxaban group received rivaroxaban PO 10 mg qd for 35±4 days (and subQ placebo for 10±4 days).

In efficacy outcome analyses, at 10±4 days, rivaroxaban was non-inferior to enoxaparin (RR 0.97; 95% CI, 0.71 to 1.31, P=0.003 for non-inferiority). Over the extended duration of 35±4 days, rivaroxaban was superior to enoxaparin (RR 0.77; 95% CI, 0.62 to 0.96, P=0.02).

In safety outcome analyses, the rivaroxaban cohort had an increased bleeding risk during both day 1 to 10 (RR 2.3; 95% CI, 1.63 to 3.17, P<0.001) and day 1 to 35 (RR 2.5; 95% CI, 1.85 to 3.25, P<0.001).

Combining efficacy and safety, the study found no net clinical benefit of rivaroxaban over enoxaparin.

In sum: Preventing thromboembolism in acutely ill hospitalized patients is a balancing act between reducing clot formation and the increasing bleeding risk. As some studies have shown the risk of thromboembolism persists after discharge from the hospital, this study compared thromboprophylaxis with standard-duration enoxaparin vs. extended-duration rivaroxaban

For preventing thromboembolism, rivaroxaban was non-inferior to enoxaparin over the standard-duration, and superior to enoxaparin over the extended-duration. However, rivaroxaban was also associated a higher risk of clinically relevant bleeding compared to enoxaparin. The study did not establish a net clinical benefit of choosing rivaroxaban over enoxaparin after accounting for both efficacy and safety.

This study affirms that an optimal treatment for thromboprophylaxis has yet to emerge. Better patient stratification based on bleeding risks is needed in order to maximize the clinical benefit of rivaroxaban.

Click to read the study in NEJM

By Xiaozhou Liu and Mitalee Patil

More from this author: Long term functional outcomes similar with surgery, radiotherapy in prostate cancer patients

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain.

[/tab]

[/tabs]

Tags: enoxapainheparinrivaroxabanthromboembolism
Previous Post

Ramipril increases pain-free walking time in patients with peripheral artery disease

Next Post

Pre-operative discussion of analgesic goals improves pediatric post-operative pain management

RelatedReports

Use of aspirin for primary prevention linked to increased risk of intracranial hemorrhage
Cardiology

Direct oral anticoagulants increase bleeding risk after intracerebral hemorrhage in patients with atrial fibrillation

May 2, 2025
#VisualAbstract: Reduced-Dose was Not Non-Inferior to Full-Dose Direct Oral Anticoagulants in Venous Thromboembolism Patients
StudyGraphics

#VisualAbstract: Reduced-Dose was Not Non-Inferior to Full-Dose Direct Oral Anticoagulants in Venous Thromboembolism Patients

March 10, 2025
Image-guided percutaneous drainage of pericardial effusions is safe and effective
Cardiology

Abelacimab reduces bleeding risk compared to rivaroxaban in atrial fibrillation

March 7, 2025
No significant increased risk of bladder cancer with pioglitazone use
Pharma

Direct oral anticoagulants have similar bleeding risk compared with aspirin

February 10, 2025
Next Post

Pre-operative discussion of analgesic goals improves pediatric post-operative pain management

Chlorhexidine bathing significantly reduces the development of hospital-acquired blood-stream infections

Intravenous omeprazole after endoscopy reduces rebleeding in patients with peptic ulcers [Classics Series]

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Lactated Ringer’s Solution Does Not Improve Outcomes Relative to Normal Saline
  • 2MM: AI Roundup – FDA’s AI Push, Trial Speedups with Real-World Data, Smart Surgical Monitors, and Regulatory Overhaul Begins [July 2nd, 2025]
  • The Scan by 2 Minute Medicine®: Celebrity diagnoses spur screenings, athlete mental-health push, reality-TV heart lesson, and a sitcom PSA wave
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.